Lung carcinoma with EGFR mutation - Revision history

Michael: /* See also */

2019-12-31T02:19:45Z

Michael: /* General */

2018-09-07T16:44:29Z

General

← Older revision		Revision as of 16:44, 7 September 2018
Line 4:		Line 4:
	*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].		*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].
	**Testing done together with ALK.		**Testing done together with ALK.
	*EGRF mutation excludes ALK rearrangement.<ref name=pmid23729361>{{Cite journal \| last1 = Gainor \| first1 = JF. \| last2 = Varghese \| first2 = AM. \| last3 = Ou \| first3 = SH. \| last4 = Kabraji \| first4 = S. \| last5 = Awad \| first5 = MM. \| last6 = Katayama \| first6 = R. \| last7 = Pawlak \| first7 = A. \| last8 = Mino-Kenudson \| first8 = M. \| last9 = Yeap \| first9 = BY. \| title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. \| journal = Clin Cancer Res \| volume = 19 \| issue = 15 \| pages = 4273-81 \| month = Aug \| year = 2013 \| doi = 10.1158/1078-0432.CCR-13-0318 \| PMID = 23729361 }}</ref>		*EGRF mutation excludes [[Lung carcinoma with ALK rearrangement\|ALK rearrangement]].<ref name=pmid23729361>{{Cite journal \| last1 = Gainor \| first1 = JF. \| last2 = Varghese \| first2 = AM. \| last3 = Ou \| first3 = SH. \| last4 = Kabraji \| first4 = S. \| last5 = Awad \| first5 = MM. \| last6 = Katayama \| first6 = R. \| last7 = Pawlak \| first7 = A. \| last8 = Mino-Kenudson \| first8 = M. \| last9 = Yeap \| first9 = BY. \| title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. \| journal = Clin Cancer Res \| volume = 19 \| issue = 15 \| pages = 4273-81 \| month = Aug \| year = 2013 \| doi = 10.1158/1078-0432.CCR-13-0318 \| PMID = 23729361 }}</ref>

	Treatement:<ref name=pmid20887192>{{Cite journal \| last1 = da Cunha Santos \| first1 = G. \| last2 = Shepherd \| first2 = FA. \| last3 = Tsao \| first3 = MS. \| title = EGFR mutations and lung cancer. \| journal = Annu Rev Pathol \| volume = 6 \| issue = \| pages = 49-69 \| month = \| year = 2011 \| doi = 10.1146/annurev-pathol-011110-130206 \| PMID = 20887192 }}</ref>		Treatement:<ref name=pmid20887192>{{Cite journal \| last1 = da Cunha Santos \| first1 = G. \| last2 = Shepherd \| first2 = FA. \| last3 = Tsao \| first3 = MS. \| title = EGFR mutations and lung cancer. \| journal = Annu Rev Pathol \| volume = 6 \| issue = \| pages = 49-69 \| month = \| year = 2011 \| doi = 10.1146/annurev-pathol-011110-130206 \| PMID = 20887192 }}</ref>

Michael at 13:34, 20 June 2017

2017-06-20T13:34:20Z

← Older revision		Revision as of 13:34, 20 June 2017
Line 1:		Line 1:
	'''Lung ~~adenocarcinoma~~ with EGFR mutation''' is a molecular subtype of [[lung adenocarcinoma]].		'''Lung carcinoma with EGFR mutation''' is a molecular subtype of [[lung carcinoma]]. Morphologically, these tumours are typically [[adenocarcinoma]]s.

	==General==		==General==

Michael at 17:58, 18 June 2017

2017-06-18T17:58:09Z

← Older revision		Revision as of 17:58, 18 June 2017
Line 1:		Line 1:
	'''Lung adenocarcinoma with EGFR ~~rearrangement~~''' is a molecular subtype of [[lung adenocarcinoma]].		'''Lung adenocarcinoma with EGFR mutation''' is a molecular subtype of [[lung adenocarcinoma]].

	==General==		==General==
Line 5:		Line 5:
	**Testing done together with ALK.		**Testing done together with ALK.
	*EGRF mutation excludes ALK rearrangement.<ref name=pmid23729361>{{Cite journal \| last1 = Gainor \| first1 = JF. \| last2 = Varghese \| first2 = AM. \| last3 = Ou \| first3 = SH. \| last4 = Kabraji \| first4 = S. \| last5 = Awad \| first5 = MM. \| last6 = Katayama \| first6 = R. \| last7 = Pawlak \| first7 = A. \| last8 = Mino-Kenudson \| first8 = M. \| last9 = Yeap \| first9 = BY. \| title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. \| journal = Clin Cancer Res \| volume = 19 \| issue = 15 \| pages = 4273-81 \| month = Aug \| year = 2013 \| doi = 10.1158/1078-0432.CCR-13-0318 \| PMID = 23729361 }}</ref>		*EGRF mutation excludes ALK rearrangement.<ref name=pmid23729361>{{Cite journal \| last1 = Gainor \| first1 = JF. \| last2 = Varghese \| first2 = AM. \| last3 = Ou \| first3 = SH. \| last4 = Kabraji \| first4 = S. \| last5 = Awad \| first5 = MM. \| last6 = Katayama \| first6 = R. \| last7 = Pawlak \| first7 = A. \| last8 = Mino-Kenudson \| first8 = M. \| last9 = Yeap \| first9 = BY. \| title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. \| journal = Clin Cancer Res \| volume = 19 \| issue = 15 \| pages = 4273-81 \| month = Aug \| year = 2013 \| doi = 10.1158/1078-0432.CCR-13-0318 \| PMID = 23729361 }}</ref>

			Treatement:<ref name=pmid20887192>{{Cite journal \| last1 = da Cunha Santos \| first1 = G. \| last2 = Shepherd \| first2 = FA. \| last3 = Tsao \| first3 = MS. \| title = EGFR mutations and lung cancer. \| journal = Annu Rev Pathol \| volume = 6 \| issue = \| pages = 49-69 \| month = \| year = 2011 \| doi = 10.1146/annurev-pathol-011110-130206 \| PMID = 20887192 }}</ref>
			*[[Tyrosine kinase inhibitors]].

	===Associations===		===Associations===

Michael: Michael moved page Lung carcinoma with EGFR rearrangement to Lung carcinoma with EGFR mutation: redirect

2017-06-18T17:56:32Z

Michael moved page Lung carcinoma with EGFR rearrangement to Lung carcinoma with EGFR mutation: redirect

← Older revision

Revision as of 17:56, 18 June 2017

Michael: /* General */

2017-06-18T17:55:56Z

General

← Older revision		Revision as of 17:55, 18 June 2017
Line 4:		Line 4:
	*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].		*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].
	**Testing done together with ALK.		**Testing done together with ALK.
			*EGRF mutation excludes ALK rearrangement.<ref name=pmid23729361>{{Cite journal \| last1 = Gainor \| first1 = JF. \| last2 = Varghese \| first2 = AM. \| last3 = Ou \| first3 = SH. \| last4 = Kabraji \| first4 = S. \| last5 = Awad \| first5 = MM. \| last6 = Katayama \| first6 = R. \| last7 = Pawlak \| first7 = A. \| last8 = Mino-Kenudson \| first8 = M. \| last9 = Yeap \| first9 = BY. \| title = ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. \| journal = Clin Cancer Res \| volume = 19 \| issue = 15 \| pages = 4273-81 \| month = Aug \| year = 2013 \| doi = 10.1158/1078-0432.CCR-13-0318 \| PMID = 23729361 }}</ref>

	===Associations===		===Associations===

Michael: /* General */

2017-06-18T17:53:19Z

General

← Older revision		Revision as of 17:53, 18 June 2017
Line 3:		Line 3:
	==General==		==General==
	*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].		*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].
			**Testing done together with ALK.

	===Associations===		===Associations===

Michael: /* General */

2017-06-18T17:44:34Z

General

← Older revision		Revision as of 17:44, 18 June 2017
Line 2:		Line 2:

	==General==		==General==
	*EGFR mutations are most closely associated with [[lung adenocarcinoma]].
	*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].		*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].

			===Associations===
	Varies significantly by population:<ref name=pmid27738317>{{Cite journal \| last1 = Zhang \| first1 = YL. \| last2 = Yuan \| first2 = JQ. \| last3 = Wang \| first3 = KF. \| last4 = Fu \| first4 = XH. \| last5 = Han \| first5 = XR. \| last6 = Threapleton \| first6 = D. \| last7 = Yang \| first7 = ZY. \| last8 = Mao \| first8 = C. \| last9 = Tang \| first9 = JL. \| title = The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. \| journal = Oncotarget \| volume = 7 \| issue = 48 \| pages = 78985-78993 \| month = Nov \| year = 2016 \| doi = 10.18632/oncotarget.12587 \| PMID = 27738317 }}</ref>		Varies significantly by population:<ref name=pmid27738317>{{Cite journal \| last1 = Zhang \| first1 = YL. \| last2 = Yuan \| first2 = JQ. \| last3 = Wang \| first3 = KF. \| last4 = Fu \| first4 = XH. \| last5 = Han \| first5 = XR. \| last6 = Threapleton \| first6 = D. \| last7 = Yang \| first7 = ZY. \| last8 = Mao \| first8 = C. \| last9 = Tang \| first9 = JL. \| title = The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. \| journal = Oncotarget \| volume = 7 \| issue = 48 \| pages = 78985-78993 \| month = Nov \| year = 2016 \| doi = 10.18632/oncotarget.12587 \| PMID = 27738317 }}</ref>
	{\| class="wikitable sortable"		{\| class="wikitable sortable"

Michael: /* See also */

2017-06-18T17:44:07Z

Michael: /* General */

2017-06-18T17:42:45Z

General

← Older revision		Revision as of 17:42, 18 June 2017
Line 4:		Line 4:
	*EGFR mutations are most closely associated with [[lung adenocarcinoma]].		*EGFR mutations are most closely associated with [[lung adenocarcinoma]].
	*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].		*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]].

			Varies significantly by population:<ref name=pmid27738317>{{Cite journal \| last1 = Zhang \| first1 = YL. \| last2 = Yuan \| first2 = JQ. \| last3 = Wang \| first3 = KF. \| last4 = Fu \| first4 = XH. \| last5 = Han \| first5 = XR. \| last6 = Threapleton \| first6 = D. \| last7 = Yang \| first7 = ZY. \| last8 = Mao \| first8 = C. \| last9 = Tang \| first9 = JL. \| title = The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. \| journal = Oncotarget \| volume = 7 \| issue = 48 \| pages = 78985-78993 \| month = Nov \| year = 2016 \| doi = 10.18632/oncotarget.12587 \| PMID = 27738317 }}</ref>
			{\| class="wikitable sortable"
			! Population
			! Prevalence
			! Category
			\|-
			\| Europe
			\| 14%
			\| Geographic
			\|-
			\| China
			\| 38%
			\| Geographic
			\|-
			\| Females
			\| 44%
			\| Patient characteristics
			\|-
			\| Males
			\| 24%
			\| Patient characteristics
			\|-
			\| Non-smokers
			\| 49%
			\| Patient characteristics
			\|-
			\| Smokers or past smokers
			\| 22%
			\| Patient characteristics
			\|-
			\| Adenocarcinoma
			\| 38%
			\| Pathology
			\|-
			\| Non-adenocarcinoma
			\| 12%
			\| Pathology
			\|}

	==Sign out==		==Sign out==

← Older revision		Revision as of 02:19, 31 December 2019
Line 58:		Line 58:
	*[[Lung carcinoma with ALK rearrangement]].		*[[Lung carcinoma with ALK rearrangement]].
	*[[Epidermal growth factor receptor inhibitors]].		*[[Epidermal growth factor receptor inhibitors]].
			*[[ROS1-rearranged non-small cell lung carcinoma]].

	==References==		==References==

← Older revision		Revision as of 17:44, 18 June 2017
Line 52:		Line 52:
	==See also==		==See also==
	*[[Lung carcinoma with ALK rearrangement]].		*[[Lung carcinoma with ALK rearrangement]].
			*[[Epidermal growth factor receptor inhibitors]].

	==References==		==References==